99896-31-8

Upstream product

• 94283-73-5 3-hydroxy-4-isopropoxy benzaldehyde 
• 100-39-0 benzyl bromide 
• 75-26-3 isopropyl bromide 
• 50773-56-3 3-benzyloxy-4-hydroxybenzaldehyde 
• 139-85-5 3,4-dihydroxybenzaldehyde 
• 100-44-7 benzyl chloride 

Downstream Products

• 147612-60-0 2-Benzyloxy-4-(bis-phenylsulfanyl-methyl)-1-isopropoxy-benzene 
• 1312673-42-9 Br^(1-)*C₃₅H₃₄O₂P⁽¹⁺⁾ 
• 1312673-51-0 (Z)-2-(benzyloxy)-4-(2-bromo-5-isopropoxystyryl)-1-isopropoxybenzene 
• 1312673-50-9 (E)-2-(benzyloxy)-4-(2-bromo-5-isopropoxystyryl)-1-isopropoxybenzene 
• 1622205-44-0 (E)-2-(benzyloxy)-1-isopropoxy-4-(2-nitrovinyl)benzene 
• 1622204-17-4 (R)-5-((2-(4-(1-(2-hydroxypropyl)piperidin-4-yl)benzamide)pyridin-4-yl)oxy)-6-isopropoxy-N-methyl-1H-indole-1-carboxamide 
• 1622206-06-7 C₃₅H₄₁N₅O₆ 
• 1622204-16-3 6-isopropoxy-N-methyl-5-((2-(4-(piperidin-4-yl)benzamide)pyridin-4-yl)oxy)-1H-indole-1-carboxamide 

Relevant academic research and scientific papers

FOURTH-GENERATION EGFR TYROSINE KINASE INHIBITOR

Provided is a compound having a tyrosine kinase inhibitory activity specific to C797S resistant mutant EGFR (particularly C797S tertiary-resistant mutant EGFR) and is useful as a C797S resistant mutant EGFR (particularly C797S mutant tertiary-resistant EG

Vanadium-Catalyzed Oxidative Intramolecular Coupling of Tethered Phenols: Formation of Phenol-Dienone Products

A mild and efficient method for the vanadium-catalyzed intramolecular coupling of tethered free phenols is described. The corresponding phenol-dienone products are prepared directly in good yields with low catalyst loadings. Electronically diverse tethered phenol precursors are well tolerated, and the catalytic method was effectively applied as the key step in syntheses of three natural products and a synthetically useful morphinan alkaloid precursor.

Design, synthesis, and evaluation of A-ring-modified lamellarin N analogues as noncovalent inhibitors of the EGFR T790M/L858R mutant

A series of A-ring-modified lamellarin N analogues were designed, synthesized, and evaluated as potential noncovalent inhibitors of the EGFR T790M/L858R mutant, a causal factor in the drug-resistant non-small cell lung cancer. Several water-soluble ammonium- or guanidinium-tethered analogues exhibited good kinase inhibitory activities. The most promising analogue, 14f, displayed an excellent inhibitory profile against the T790M/L858R mutant [IC50 (WT) = 31.8 nM; IC50 (T790M/L858R) = 8.9 nM]. The effects of A-ring-substituents on activity were rationalized by docking studies.

MONOCYCLIC PYRIDINE DERIVATIVE

The present invention provides a novel compound having FGFR inhibitory activity or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition containing the same. Specifically, the present invention provides a compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof: wherein n represents 0 to 2; A represents an arylene group or a heteroarylene group; G represents a single bond, an oxygen atom or —CH2—; E represents a nitrogen-containing non-aromatic heterocycle; R1 represents an alkoxy group or the like; R2 represents a hydrogen atom or the like; and R3 represents a hydrogen atom, an alkyl group, an alkoxy group or the like, with the proviso that when E represents an azetidine ring and R2 or R3 is present on a nitrogen atom on the azetidine ring, the R2 or R3 does not represent a hydrogen atom.

Total synthesis of plagiochin D by an intramolecular SNAr reaction

The total synthesis of plagiochin D, a macrocyclic bis(bibenzyl) compound isolated from the liverwort plagiochila acanthophylla, has been accomplished. Closure of the key 16-membered ring, which contained biphenyl ether and biaryl units, was achieved in good yield by an intramolecular SNAr reaction. The Suzuki and Wittig protocols proved to be powerful tools for the construction of a linear precursor that was crucial for ring cyclization. Copyright

IMIDAZOPYRAZINE TYROSINE KINASE INHIBITORS

Compounds of the formula (I) and pharmaceutically acceptable salts thereof, wherein Q1 and R1 are defined herein, inhibit the IGF-1R enzyme and are useful for the treatment and/or prevention of various diseases and conditions that respond to treatment by inhibition of tyrosine kinases.

STUDIES WITH PLANT CELL CULTURES OF PODOPHYLLUM PELTATUM L. II. BIOTRANSFORMATION OF DIBENZYLBUTANOLIDES TO LIGNANS. DEVELOPMENT OF A "BIOLOGICAL FACTORY" FOR LIGNAN SYNTHESIS

An efficient and versatile synthetic route to appropriate dibenzylbutanolides suitable for biotransformation to lignans as potential intermediates for the syntheses of the clinical anti-cancer drug etoposide has been developed.Biotransformation of such substrates, for example 10, with cell cultures of Podophyllum peltatum affords a potentially exciting route to this drug.Of particular significance is the development of a semi-continuous fermentation process with these plant cells wherein successive additions of substrate and isolation of end products can be pursued with a given batch of cells and over a period of several months.Biotransformation times for the conversion of 10 to 11 and 12 are short (usually 24-48 h).Although conditions have not yet optimized, this "biological factory" for lignan synthesis provides a novel approach for the use of plant cells, in combination with chemistry, for continuous and large scale production of such metabolites.

On the Synthesis of 2,12-Dimethoxy-6,7,8,9-tetrahydro-5H-dibenzazonine-3,11-diol and Other Bridged Biphenyldiols and the E.S.R. of Their Oxidation Products in Relation to the Biosynthesis of Erythrina Alkaloids

An improved synthesis in described for the dibenzazonine precursor of erysodienone.Other biphenyl-4,4'-diols, bridged by two, three and five atoms, were also prepared.E.s.r. examination of the oxidation of these compounds produced spectra of the 9,10-dihydrophenanthrene-4,4'-semiquinone system, hitherto unrecorded, but semiquinone spectra could not be obtained from the other diols.